Article | May 24, 2023

How Technology Can Empower CAR T-Cell Therapy Clinical Trials

GettyImages-1366661187 cell tech

Since 2017, the U.S. Food and Drug Administration has approved six CAR T-cell treatments for blood cancers, including lymphomas, some forms of leukemia, and multiple myeloma. Touted as one of the most exciting medical advances of the past decade, CAR T-cell therapies provide hope for patients facing relapse or unresponsive cancer, where conventional treatments like chemotherapy, surgery, or radiation have fallen short. Due to its success, there has been an uptick in sponsors launching clinical trials for the targeted form of therapy.

According to reports, there are over 1,000 CAR T-cell trials registered with the FDA, with 627 currently active, and the number of trial starts has grown 38.7% year over year. However, many of these trials are still in Phase 1, meaning that patients whose cancer isn’t responding fast enough or who have already relapsed can’t afford delays. Explore how innovative technologies are empowering advancements in CAR T-cell therapy, enhancing patient outcomes, and streamlining trial processes.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader